GrantExec

Grants for Independent school districts - Health

Explore 2,656 grant opportunities

Notice of Intent to Publish a Funding Opportunity Announcement for Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
$400,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Feb 28, 2025

Date Added

Nov 26, 2024

This funding opportunity provides financial support for early-career researchers in genomics to advance innovative projects that contribute to the field and promote diversity within the research community.

Health
State governments
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)
$100,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

May 7, 2024

Date Added

May 12, 2020

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Education
State governments
Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed)
$500,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

Jun 10, 2024

Date Added

Mar 14, 2024

Notice of Funding Opportunity Description Background The accumulation of misprocessed and aberrant proteins is a defining characteristic of various neurodegenerative conditions, such as AD and frontotemporal lobar degeneration (FTLD). These atypical proteins may arise from various factors, such as somatic mutations, environmental changes, genomic instability, irregular RNA processing, and proteolytic cleavages, as well as incorrect folding and post-translational modifications. For instance, many recent proteome and transcriptome profiling of AD brains reveals RNA splicing dysfunction and abnormal accumulation of U1 small nuclear ribonucleoprotein (snRNP) and transactive response DNA-binding protein 43 (TDP-43). In AD, U1-70K and its N-terminal 40-KDa fragment (N40K) is one of the most abundant proteins in the insoluble fraction of cell lysates. TDP-43 is an RNA-binding protein. In AD, TDP-43 pathology is observed in approximately 25-50% of cases, particularly in cases with co-morbidities such as Lewy body dementia or hippocampal sclerosis. However, the relationship between U1snRNP/TDP-43 and AD pathology is complex and not fully understood. The disruption of RNA processing is thought to be one possible mechanism to cause the accumulation of misprocessed proteins, which can lead to altered expression of genes involved in AD pathology, including amyloid precursor protein (APP), tau, and synaptic proteins. Understanding the mechanisms underlying the dysregulation of misprocessed proteins in neurodegenerative diseases will be important for developing effective therapies. Approaches that target the production or aggregation of misprocessed proteins, or that promote their clearance or degradation, may be effective in preventing or slowing disease progression. Purpose This NOFO invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. This NOFO encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of AD/ADRD. Research Objectives This NOFO aims to provide a proof-of-principal for a novel strategy to identify misprocessed and aberrant proteins in Tau diseases using the proteogenomic approach. Proteogenomics is an integrated approach that combines proteomics and genomics data. In proteogenomics, genomic and transcriptomic experiments are more closely integrated to identify potential protein coding and non-coding regions in the genome. These regions are then validated using mass spectrometry-based proteomics. Proteogenomics has emerged as a powerful tool for investigating the role of protein homeostasis in AD pathogenesis, especially in the context of mis-translated and mis-repaired proteins. However, relying solely on misprocessed protein levels to draw conclusions about biological processes is unlikely to be reliable. Therefore, an intermediate layer of functional validation is essential to transform proteogeomic data into meaningful biological information. As a result, the objective of this NOFO is not only to confirm changes in protein abundance using other methods, but also to assess the biological effects of those changes in some model systems, especially in the area of tauopathies, to ensure high interlaboratory reproducibility. Using the proteogenomics approach, this NOFO aims to accomplish the following: Create a comprehensive database of misprocessed and aberrant proteins in selected mouse models of human Tau diseases. Cross-validate the presence of misprocessed and aberrant proteins in human AD/ADRD brains. Identify new molecular pathways and novel misprocessed protein-protein interaction networks that are not currently in most datasets. Define novel mechanisms through which misprocessed and aberrant proteins influence the onset and progression of neurodegeneration in tauopathies. Identify disease specific therapeutic targets in neurodegenerative diseases. It is expected that applications responding to this initiative will use the latest cell-type-specific labeling and proteogenomic techniques with suitable model systems to understand the etiology of tauopathies in aging and AD.

Health
State governments
Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)
$200,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 4, 2024

Date Added

Aug 5, 2024

This funding opportunity supports researchers exploring the mechanisms of Treponema pallidum, the bacteria responsible for syphilis, to address the rising rates of sexually transmitted infections and improve understanding of its pathogenesis.

Health
State governments
Lethal Means Safety Suicide Prevention Research in Healthcare and Community Settings (R34 Clinical Trial Required)
$1,500,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Jan 23, 2025

Date Added

Mar 19, 2024

This grant provides funding for research projects that test strategies to reduce suicide risk by promoting safe storage of lethal means, such as firearms, in healthcare and community settings.

Health
State governments
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
$750,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 21, 2024

Date Added

Mar 11, 2021

The "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" program supports the development of in vitro and ex vivo assays to identify and characterize new therapeutic agents for neurological and neuromuscular disorders, with a focus on creating robust screening methods for promising neurotherapeutics.

Health
State governments
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
$275,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Dec 5, 2024

Date Added

Apr 4, 2024

This funding opportunity supports exploratory preclinical studies to evaluate the effectiveness of therapeutic agents for rare diseases affecting fewer than 200,000 people in the U.S., aiming to advance these treatments toward clinical trials.

Health
State governments
NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed)
$250,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 1, 2024

Date Added

Jan 29, 2024

The "NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research" grant aims to support educational and mentoring activities that encourage individuals, especially those from diverse backgrounds, to pursue research careers in biomedical, behavioral, and clinical sciences, with a particular focus on improving the recruitment, preparation, and retention of clinician investigators.

Health
State governments
NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
$500,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Jun 20, 2025

Date Added

Jul 26, 2022

This grant provides funding to early-career researchers in mental health to support innovative projects that advance the understanding and treatment of mental illnesses.

Health
State governments
FY 2024 Notice of Funding Opportunity for NGO Programs in South Sudan Responding to the Ongoing Sudan Crisis
$150,000
SANOFI
Private

Application Deadline

May 10, 2024

Date Added

May 2, 2024

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.

Health
Exclusive - see details
Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional)
$825,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

Jun 24, 2024

Date Added

Mar 19, 2024

"Fluctuating cognition can occur in many types of dementia and is a core clinical feature of Dementia with Lewy Bodies. Cognitive fluctuations can last from seconds to days, are unpredictable (e.g., do not just occur in the evenings, as with sun-downing), and are associated with poor daily functioning for the patient. A number of small studies have suggested that cognitive fluctuations in subjects with dementia may be related to epileptiform discharges and impaired oscillatory activity on EEG, but it is not clear that these are the only factors involved in patient populations that often experience dysautonomia, orthostasis, and sleep disturbances. The etiology of cognitive fluctuations may be multi-factorial and may vary in different dementia populations. Understanding the physiology related to cognitive fluctuations is a critical next step to the development of treatment approaches and improving quality of life for these patients. This initiate would encourage research that will better characterize the physiology responsible for cognitive fluctuations in ADRD populations. Given their variable appearance and time course, it is anticipated that wearable digital devices will be important for capturing fluctuations in a timely fashion, and applicants should consider incorporating those device(s) capable of acquiring the relevant data to support the hypothesized mechanism(s). Applicants may focus on assessing multiple mechanisms in a specific ADRD population, or may chose to compare mechanisms across multiple types of ADRDs. "

Health
State governments
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Jan 12, 2025

Date Added

Oct 30, 2023

This funding opportunity supports research on the ethical, legal, and social implications of human genetics and genomics, particularly focusing on diverse perspectives and community engagement.

Education
State governments
Notice of Intent to Publish a Funding Opportunity Announcement for Academic Career Excellence (ACE) Award (K32 Independent Clinical Trial Not Allowed)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Jun 12, 2025

Date Added

Dec 27, 2024

This funding opportunity supports early-stage postdoctoral researchers in cancer research by providing resources for structured training and professional development to advance their scientific careers.

Health
State governments
Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 2, 2024

Date Added

Jan 24, 2024

(Reissue PAR-21-056) The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Health
State governments
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Aug 14, 2025

Date Added

Aug 26, 2024

This grant provides funding for researchers to study how HIV and substance use disorder affect brain cell function, with the goal of uncovering new treatment strategies for individuals facing these combined challenges.

Education
State governments
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
Contact for amount
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 30, 2024

Date Added

Feb 3, 2024

This funding opportunity supports researchers in conducting multi-site clinical trials to investigate the effects of natural products, such as botanicals and dietary supplements, on health, requiring a comprehensive plan for trial management and data analysis.

Health
State governments
NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required)
Contact for amount
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

May 7, 2024

Date Added

May 8, 2023

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.

Health
State governments
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 5, 2024

Date Added

Aug 15, 2023

This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.

Education
State governments
Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Dec 15, 2024

Date Added

Nov 28, 2022

This funding opportunity supports researchers conducting multisite clinical trials and observational studies focused on women, children, pregnant and lactating individuals, and persons with disabilities, utilizing NICHD's established network infrastructure.

Health
State governments
Notice of Intent to Publish a Funding Opportunity for Maximizing the Scientific Value of Data Generated by the Environmental influences on Child Health Outcomes (ECHO) Program: Dissertation Grant (R36)
$45,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Mar 17, 2025

Date Added

Nov 26, 2024

This funding opportunity supports doctoral candidates conducting research on maternal and child health using a large dataset to explore the impact of early environmental exposures on child health outcomes.

Health
State governments